Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 1, 2012Wed, February 29, 2012Tue, February 28, 2012Mon, February 27, 2012Sat, February 25, 2012Fri, February 24, 2012Thu, February 23, 2012Wed, February 22, 2012Tue, February 21, 2012Mon, February 20, 2012Sat, February 18, 2012Fri, February 17, 2012Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference
Published in Health and Fitness on Thursday, February 23rd 2012 at 14:11 GMT by Market Wire
Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference -- HAYWARD, Calif., Feb. 23, 2012 /PRNewswire/ --
Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference
HAYWARD, Calif., Feb. 23, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: [ ANTH ]), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that Paul F. Truex, Anthera's President and Chief Executive Officer, will provide a corporate presentation at the Citi Global Health Care Conference in New York, NY on Monday, February 27, 2012, at approximately 2:00 pm Eastern Time.
Citi 2012 Global Health Care Conference Presentation
Date/Time: Monday, February 27, at 2:00 pm Eastern Time
Location: The Waldorf Astoria Hotel
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., [ bnery@anthera.com ] or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.anthera.com ]
